Literature DB >> 26514966

Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB/c mice.

Jian-Ping Shi1,2, Shui-Xiu Li1, Zheng-Lai Ma3, Ai-Li Gao4, Yan-Jun Song1, Hong Zhang5.   

Abstract

OBJECTIVE: To evaluate the acute and sub-chronic toxicity of intravenously administered tetrandrine (TET) in female BALB/c mice.
METHODS: The median lethal dose (LD50) of intravenously administered TET was calculated in mice using Dixon's up-and-down method. In the acute toxicity study, mice were intravenously administered with TET at a single dose of 20, 100, 180, 260 and 340 mg/kg, respectively and were evaluated at 14 days after administration. In the sub-acute toxicity study, mice were intravenously administered various doses of TET (30, 90 and 150 mg/kg) each day for 14 consecutive days. Clinical symptoms, mortality, body weight, serum biochemistry, organ weight and histopathology were examined at the end of the experiment, as well as after a 1-week recovery period. RESULT: LD50 was found to be 444.67±35.76 mg/kg. In the acute toxicity study, no statistically signifificant differences in body weight, blood biochemistry, or organ histology were observed between the administration and control groups when mice were intravenously administered with single dose at 20, 100, 180, 260 and 340 mg/kg of TET (P >0.05). In the sub-acute toxicity study, no signifificant changes in body weight, biochemistry and organ histology were observed with up to 90 mg/kg of TET compared with the control group (P >0.05), however, in the 150 mg/kg administered group, TET induced transient toxicity to liver, lungs and kidneys, but withdrawal of TET can lead to reversal of the pathological conditions.
CONCLUSIONS: The overall fifindings of this study indicate that TET is relatively non-toxic from a single dose of 20, 100, 180, 260 or 340 mg/kg, and that up to 90 mg/kg daily for 14 consecutive days can be considered a safe application dose.

Entities:  

Keywords:  Chinese medicine; acute and sub-chronic toxicity; female BALB/c mice; tetrandrine

Mesh:

Substances:

Year:  2015        PMID: 26514966     DOI: 10.1007/s11655-015-2303-2

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  21 in total

1.  Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells.

Authors:  Yan Fang Sun; Michael Wink
Journal:  Phytomedicine       Date:  2014-05-22       Impact factor: 5.340

2.  Tetrandrine-induced apoptosis in rat primary hepatocytes is initiated from mitochondria: caspases and endonuclease G (Endo G) pathway.

Authors:  Cai Yan; Qi Xin-Ming; Gong Li-Kun; Liu Lin-Lin; Chen Fang-Ping; Xiao Ying; Wu Xiong-Fei; Li Xiang-Hong; Ren Jin
Journal:  Toxicology       Date:  2005-10-24       Impact factor: 4.221

3.  Pulmonary toxicity and metabolic activation of tetrandrine in CD-1 mice.

Authors:  Hua Jin; Liang Li; Dafang Zhong; Jia Liu; Xiaoyan Chen; Jiang Zheng
Journal:  Chem Res Toxicol       Date:  2011-11-11       Impact factor: 3.739

4.  Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps.

Authors:  Hong Zhang; Aili Gao; Fengxia Li; Gehua Zhang; Hon In Ho; Wanqing Liao
Journal:  Yakugaku Zasshi       Date:  2009-05       Impact factor: 0.302

5.  ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes.

Authors:  Xin-ming Qi; Ling-ling Miao; Yan Cai; Li-kun Gong; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2013-07-29       Impact factor: 6.150

Review 6.  Cell signalling and the glutathione redox system.

Authors:  Giuseppe Filomeni; Giuseppe Rotilio; Maria Rosa Ciriolo
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

7.  Tetrandrine attenuates lipopolysaccharide-induced fulminant hepatic failure in D-galactosamine-sensitized mice.

Authors:  Xia Gong; Fu-ling Luo; Li Zhang; Hong-zhong Li; Meng-jiao Wu; Xiao-hui Li; Bin Wang; Ning Hu; Chang-dong Wang; Jun-qing Yang; Jing-yuan Wan
Journal:  Int Immunopharmacol       Date:  2009-12-28       Impact factor: 4.932

8.  Evaluation of sub-chronic toxic effects of petroleum ether, a laboratory solvent in Sprague-Dawley rats.

Authors:  Subramani Parasuraman; Jeyabalan Sujithra; Balakrishnan Syamittra; Wong Yeng Yeng; Wu Yet Ping; Selvadurai Muralidharan; Palanimuthu Vasanth Raj; Sokkalingam Arumugam Dhanaraj
Journal:  J Basic Clin Pharm       Date:  2014-09

9.  Acute toxicity of amorphous silica nanoparticles in intravenously exposed ICR mice.

Authors:  Yang Yu; Yang Li; Wen Wang; Minghua Jin; Zhongjun Du; Yanbo Li; Junchao Duan; Yongbo Yu; Zhiwei Sun
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

10.  Antinociceptive effect of tetrandrine on LPS-induced hyperalgesia via the inhibition of IKKβ phosphorylation and the COX-2/PGE₂ pathway in mice.

Authors:  Hengguang Zhao; Fuling Luo; Hongzhong Li; Li Zhang; Yongfen Yi; Jingyuan Wan
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

View more
  7 in total

Review 1.  Research Progress on Reversing Multidrug Resistance in Tumors by Using Chinese Medicine.

Authors:  Huan-Dong Zhao; Hong-Juan Xie; Jian Li; Cai-Ping Ren; Yu-Xiang Chen
Journal:  Chin J Integr Med       Date:  2018-06-02       Impact factor: 1.978

2.  Synthesis, biological evaluation and toxicity of novel tetrandrine analogues.

Authors:  Ramona Schütz; Martin Müller; Franz Geisslinger; Angelika Vollmar; Karin Bartel; Franz Bracher
Journal:  Eur J Med Chem       Date:  2020-09-04       Impact factor: 6.514

3.  Quantitative MALDI Imaging of Spatial Distributions and Dynamic Changes of Tetrandrine in Multiple Organs of Rats.

Authors:  Weiwei Tang; Jun Chen; Jie Zhou; Junyue Ge; Ying Zhang; Ping Li; Bin Li
Journal:  Theranostics       Date:  2019-01-25       Impact factor: 11.556

Review 4.  Progress on structural modification of Tetrandrine with wide range of pharmacological activities.

Authors:  Liuying Mo; Fan Zhang; Feng Chen; Lei Xia; Yi Huang; Yuemi Mo; Lingqiu Zhang; Daquan Huang; Shunli He; Jiagang Deng; Erwei Hao; Zhengcai Du
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 5.  Targeting the two-pore channel 2 in cancer progression and metastasis.

Authors:  Kathryn A Skelding; Daniel L Barry; Danielle Z Theron; Lisa F Lincz
Journal:  Explor Target Antitumor Ther       Date:  2022-02-28

Review 6.  A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).

Authors:  Yueping Jiang; Min Liu; Haitao Liu; Shao Liu
Journal:  Phytochem Rev       Date:  2020-04-24       Impact factor: 5.374

Review 7.  Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.

Authors:  Paula M Heister; Robin N Poston
Journal:  Pharmacol Res Perspect       Date:  2020-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.